Deficiency of FLOT2 in LICs prolongs survival in CML. (A-B) Leukocyte counts × 10³/μL in PB (P = .0193; t test; n = 11-13) 14 days after transplantation (A) and Kaplan-Meier-style survival curve (B) of C57BL/6 recipient mice transplanted with BM from C57BL/6 (WT; solid line, red) or Flot2 KO (dotted line, blue) mice, transduced with BCR–ABL1-expressing retrovirus (P < .0001; log-rank test; n = 9). (C-D) Percentage of total leukocytes (P = .0275; t test; n = 3) (C) and absolute number per femur of GFP⁺ (BCR-ABL1⁺) WT (red) or Flot2 KO (blue) LKS cells (P = .0462; t test; n = 3) (D), which homed to the BM of WT mice 18 hours after transplantation. (E) Quantification of proviral integration sites, as tested by long-distance inverse (LDI) PCR on DNA derived from spleens of WT mice which had been transplanted with WT (red) or Flot2 KO (blue) BCR–ABL1-transduced BM in the CML model (P = .0007; t test; n = 12). (F) Kaplan–Meier-style survival curve of WT recipient mice transplanted with BM from WT (red) or Flot2 KO (blue) mice, transduced with BCR–ABL1-expressing retrovirus. An equal number of cells (2.5 × 10⁵) was injected either IV (i.v.) or intrafemorally (i.f.) (P = .0035; log-rank test; n = 5-8).